Stroke

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

The Amulet IDE Trial is the first trial to offer a head-to-head comparison of the Amplatzer Amulet occluder from Abbot against the Watchman device from Boston Scientific for left atrial appendage occlusion.

Data from the Salt Substitute and Stroke Study suggest switching from regular salt to a salt substitute could reduce the risk of stroke by 14% and investigators believe these results can be applied to patient populations across the world.

Despite increasing detection of atrial fibrillation and rates of anticoagulation, continuous electrocardiographic monitoring with an implantable loop recorder did not significantly reduce risk of stroke in the LOOP study.

An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.

The vagus nerve stimulation system is the first of its kind stroke rehabilitation system, after supporting data from the VNS-REHAB trial suggested its efficacy in improving FMA-UE scores.

All NOACs had a lower risk of stroke or SE compared to warfarin, including apixaban, dabigatran, and rivaroxaban.

A meta-analysis with data from nearly 60k patients suggests presence of metabolic syndrome was associated with a 46% increase in risk of a second stroke and a 27% increase in risk of mortality among stroke survivors when compared to their counterparts without metabolic syndrome.

A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.

The American Heart Association and American Stroke Association recognize the important role of primary care in patient management following a stroke.

Simultaneously published in JAMA, the PER DIEM and STROKE-AF trials demonstrate the ability of Medtronic's insertable cardiac monitor, Reveal LlNQ, to improve detection of atrial fibrillation in patients with a history of stroke.

The American Heart Association and American Stroke Association have released an updated version of their guidelines for prevention of secondary stroke in patients with stroke or TIA, which had not been updated since 2014.

Results of the LAAOS III trial provide evidence suggesting left atrial appendage occlusion could reduce risk of ischemic events by nearly a third and also reduce risk of stroke by more than 40% in patients with atrial fibrillation.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.

Dr. Gregory Weiss, a cardiovascular anesthesiologist, breaks down and provides real-world perspective on the application of a recent scientific statement from the AHA and ASA on perioperative management to lower stroke risk in patients undergoing noncardiac and nonneurological procedures.

An analysis of claims data by investigators at University of Pennsylvania indicates DOACs were associated with a 36% lower risk of stroke or systemic embolism and was also associated with a reduction in risk of major bleeding.

Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.

Just ahead of the International Stroke Conference, the AHA released a scientific statement focusing on brain health and aimed at providing primary care providers an overview of factors influencing neurologic health.

Using data from the AHA's COVID-19 Cardiovascular Disease Registry, a new analysis presented at ISC 21 provides an overview of the overall risk, risk factors, and outcomes of COVID-19-related ischemic stroke among US patients.

A pair of studies from ISC 21 is providing insight into the benefits of mobile stroke units while also highlighting current barriers to widespread implementation of these units.

An interim analysis of the ANGIOCAT trial suggests immediate angiography could help preserve function and improve outcomes in the treatment of patients with stroke caused by a large vessel occlusion compared to the current standard of performing a CT scan.

A study from ISC 21 suggests Black patients using Medicare were 4% more likely to die in the first 10 years after a stroke than their white counterparts.

An analysis of the REDUCE-IT trial suggests patients on statins who were also receiving icosapent ethyl reduced their risk of an ischemic stroke by an additional 36%.